Literature DB >> 3340295

Visual system toxicity following intra-arterial chemotherapy.

M J Kupersmith1, L P Frohman, I S Choi, S H Foo, E Hiesinger, A Berenstein, A Wise, R E Carr, J Ransohoff.   

Abstract

We studied the effects of intra-arterial chemotherapy on the visual system of 29 consecutive patients with gliomas. As expected, infra-ophthalmic carotid infusion of cisplatin or carmustine (BCNU) was associated with clinically apparent anterior visual pathway lesions. Electroretinography revealed retinal dysfunction in patients without clinical abnormalities. Supra-ophthalmic carotid infusion of cisplatin or BCNU caused no retinal or optic nerve lesions. Electroretinography was abnormal in only one of these patients. Our results indicated that BCNU and cisplatin cause ischemic damage and are toxic to both retinal and neural tissue in patients with gliomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3340295     DOI: 10.1212/wnl.38.2.284

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study.

Authors:  M Poisson; J Chiras; F Fauchon; C Debussche; J Y Delattre
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

2.  Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer.

Authors:  Simon Dulz; Niels H Asselborn; Klaus-Peter Dieckmann; Cord Matthies; Walter Wagner; Jens Weidmann; Christoph Seidel; Christoph Oing; Lars A Berger; Winfried Alsdorf; Blanche Mankichian; Christian Meyer; Malte W Vetterlein; Philipp Gild; Tim A Ludwig; Armin Soave; Philipp Schriefer; Andreas Becker; Sascha A Ahyai; Karin Oechsle; Carsten Bokemeyer; Lars Wagenfeld; Margit Fisch; Michael Hartmann; Felix K-H Chun; Luis A Kluth
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-09       Impact factor: 4.553

3.  Reversible branch retinal artery occlusion following intravenous cisplatin chemotherapy for cervical carcinoma.

Authors:  Arijit Mitra; Matthew R Edmunds; Nawaz Walji; Indrajit N Fernando; Robert A H Scott; Peter Good
Journal:  Int Ophthalmol       Date:  2011-11-23       Impact factor: 2.031

4.  Negative-type electroretinogram from cisplatin toxicity.

Authors:  M F Marmor
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

5.  Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure.

Authors:  A M Spence; M S Berger; R B Livingston; F Ali-Osman; B Griffin
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

6.  Intra-arterial carboplatin chemotherapy for brain tumors: a dose escalation study based on cerebral blood flow.

Authors:  T F Cloughesy; Y P Gobin; K L Black; F Viñuela; F Taft; B Kadkhoda; F Kabbinavar
Journal:  J Neurooncol       Date:  1997-11       Impact factor: 4.130

7.  Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumor.

Authors:  David Fortin; Joseph A Salamé; Annick Desjardins; Andrew Benko
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

8.  Effects of cisplatin and ORG.2766 in chick embryonic brain cell cultures.

Authors:  A Bruinink; F Birchler
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

9.  DTI-015 produces cures in T9 gliosarcoma.

Authors:  Dennis Pietronigro; Frank Drnovsky; Humberto Cravioto; Joseph Ransohoff
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

Review 10.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.